{"page":{"totalFilteredElements":72},"studies":[{"active":true,"description":"<p class=\"MsoNormal\">ENCLOSE (Klinische Studiengruppe NAFLD): CK18 M30 als\nnicht-invasiver Marker f&#252;r subklinische Zellsch&#228;digung &#8211; prospektive Analyse\ndes Langzeitverlaufes bei NAFLD</p>","eudractNumber":null,"id":2266,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[{"name":"Caspase-cleaved fragment of CK18 (M30)","id":"mt_271"}],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2016-07-01T14:19:23+02:00","shortTitle":"NAFLD CSG","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">Pr&#228;diktion des\nAnsprechens auf Hypertherme Intraperitoneale Chemotherapie in gastrointestinalen Krebserkrankungen (Hi-STEP1)</p><p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">DRKS00028836</p>","eudractNumber":null,"id":10899,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-06T09:06:56+02:00","shortTitle":"NCT Hi-STEP1","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"<p class=\"MsoNormal\" style=\"line-height:normal;\">National Center for Tumor Diseases / German Cancer Consortium (NCT/DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER)</p><p class=\"MsoNormal\" style=\"line-height:normal;\"><b>NCT MASTER Program</b></p>","eudractNumber":null,"id":4421,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T11:14:24+01:00","shortTitle":"NCT-Studie: MASTER Programm","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker f&#252;r Risikostratifizierung, Therapiesteuerung und Vertr&#228;glichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Patientendatenintegrationsplattform der Pancreatic Cancer Alliance Bavaria (PCAB)","eudractNumber":null,"id":10521,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2023-05-26T12:31:40+02:00","shortTitle":"PCAB (Pankreasregister)","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Pr&#228;vention von fr&#252;hen Darmkrebserkrankungen - PEARL","eudractNumber":null,"id":11520,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":"NCT05541601","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2022-10-10T09:48:39+02:00","shortTitle":"PEARL","therapeutical":false,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>PERSUASION</div><div>New Prospective Expanded German Registry of Incidental Gallbladder Carcinoma (PERSUASION) a permanent platform including all kind of biliary tract cancers (BTC)</div>","eudractNumber":null,"id":9177,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"}],"mutations":[],"nctNumber":"NCT04896931","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2023-01-30T21:22:13+01:00","shortTitle":"PERSUASION","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma","eudractNumber":"2024-513317-12-00","id":9932,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-30T09:54:54+02:00","shortTitle":"PRISM-1","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:justify;\">PRODIGE\n107- ENGIC 01- COLOSOTO</p>\n\n<p class=\"MsoNormal\" align=\"center\" style=\"text-align:justify;\">A single-arm phase II\nstudy evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib\n(KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a\ndoublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated\ncolorectal adenocarcinoma</p>","eudractNumber":"2024-514030-20-00","id":11576,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2026-02-04T14:05:28+01:00","shortTitle":"PRODIGE 107-COLOSOTO","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Pre-Operative Treatment in rEseCTable cOlon canceR</div><div>(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)</div><div>Prospective, randomized, open, multicenter Phase III trial</div><div>to investigate the efficacy preoperative systemic therapy in</div><div>advanced colon cancer</div>","eudractNumber":"2023-508076-11-00","id":11330,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-01T08:30:33+02:00","shortTitle":"PROTECTOR/ Fire-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]}]}